Fiserv earnings missed by $0.61, revenue fell short of estimates
Michael Feld, Executive Vice President & President, Life Sciences at Becton Dickinson & Co (NYSE:BDX), sold 57 shares of company stock on October 27, 2025, at a price of $186.01, for a total value of $10,602.
Following the transaction, Feld directly owns 8,245 shares of Becton Dickinson & Co.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 7, 2025. For deeper insights into BDX’s valuation, financial health metrics, and exclusive analysis, investors can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, BD (Becton, Dickinson and Company) reported disappointing preliminary fourth-quarter sales results, which fell below consensus estimates. This announcement coincided with the news that the company’s Chief Financial Officer, Chris DelOrefice, will be leaving on December 5 to pursue another opportunity. RBC Capital noted that the preliminary revenue and earnings per share results were slightly below the low end of BD’s previous guidance. Meanwhile, BD introduced a new self-collection solution for HPV testing, certified under the In Vitro Diagnostic Medical Device Regulation in Europe, to facilitate at-home cervical cancer screening. Additionally, the company launched the BD Incada Connected Care Platform, an AI-enabled system designed to integrate data from its medical devices. This platform is built on Amazon Web Services infrastructure and accompanies the release of BD’s next-generation Pyxis Pro Automated Medication Dispensing Solution. Furthermore, BD has enrolled the first patient in its XTRACT Registry study to assess the real-world performance of the Rotarex Catheter System for peripheral artery disease treatment. These developments reflect BD’s ongoing efforts to innovate and expand its medical technology offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.